Literature DB >> 24074814

Severe late esophagus toxicity in NSCLC patients treated with IMRT and concurrent chemotherapy.

Chun Chen1, Wilma Uyterlinde, Jan-Jakob Sonke, Josien de Bois, Michel van den Heuvel, José Belderbos.   

Abstract

BACKGROUND AND
PURPOSE: We reported the incidence of severe late esophagus toxicity (LET) in locally advanced NSCLC patients treated with intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy. Acute esophagus toxicity (AET) and the dose to the esophagus were analyzed for their associations with severe LET.
MATERIAL AND METHODS: Two hundred and thirty-one patients treated from 2008 to 2011 with hypofractionated IMRT (66Gy/24fx) and concurrent daily low dose cisplatin were included. The association between AET and severe LET (grade ≥ 3 RTOG/EORTC) was tested through Cox-proportional-hazards model. Equivalent uniform dose (EUD) to the esophagus and the volume percentage receiving more than x Gy (Vx) were applied by Lyman-Kutcher-Burman (LKB) model.
RESULTS: A total of 171 patients were eligible for this study. Severe LET was observed in 6% patients. Both the maximum grade and the recovery rate of AET were significantly associated with severe LET. In the EUDn-LKB model, the fitted values and 95% confidence intervals (CIs) were TD50=76.1 Gy (73.2-78.6), m=0.03 (0.02-0.06) and n=0.03 (0-0.08). In the Vx-LKB model, the fitted values and 95% CIs were Tx50=23.5% (16.4-46.6), m=0.44 (0.32-0.60) and x=76.7 Gy (74.7-77.5).
CONCLUSIONS: Severe AET, EUD (n=0.03) and V76.7 to the esophagus were significantly associated with severe LET. An independent validation study is required.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Acute esophagus toxicity; Concurrent chemoradiation; IMRT; Late esophagus toxicity; NTCP; Non small cell lung cancer (NSCLC)

Mesh:

Substances:

Year:  2013        PMID: 24074814     DOI: 10.1016/j.radonc.2013.08.017

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  17 in total

Review 1.  Overcoming toxicity-challenges in chemoradiation for non-small cell lung cancer.

Authors:  Wilma Uyterlinde
Journal:  Transl Lung Cancer Res       Date:  2016-06

2.  Excessive esophageal toxicity in patients with locally advanced non-small cell lung cancer treated with concurrent hypofractionated chemoradiotherapy and 3-weekly platinum doublet chemotherapy.

Authors:  Noëlle van der Voort van Zyp; Masoma Hashimzadah; Erik Kouwenhoven; Carmen Liskamp; Christa Gadellaa-van Hooijdonk; Ellen Pouw; Jose Belderbos; Klaartje Maas; Paul van de Vaart; Mirjam Mast
Journal:  Clin Transl Radiat Oncol       Date:  2022-07-07

3.  Comparison of Myelotoxicity and Nephrotoxicity Between Daily Low-Dose Cisplatin With Concurrent Radiation and Cyclic High-Dose Cisplatin in Non-Small Cell Lung Cancer Patients.

Authors:  Zulfan Zazuli; Renate Kos; Joris D Veltman; Wilma Uyterlinde; Cristina Longo; Paul Baas; Rosalinde Masereeuw; Susanne J H Vijverberg; Anke-Hilse Maitland-van der Zee
Journal:  Front Pharmacol       Date:  2020-06-26       Impact factor: 5.810

4.  Outcome and toxicity profiles in the treatment of locally advanced lung cancer with volumetric modulated arc therapy.

Authors:  Marta Scorsetti; Piera Navarria; Fiorenza De Rose; AnnaMaria Ascolese; Elena Clerici; Ciro Franzese; Francesca Lobefalo; Giacomo Reggiori; Pietro Mancosu; Stefano Tomatis; Antonella Fogliata; Luca Cozzi
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-17       Impact factor: 4.553

5.  A lot to a little or a little to a lot-which dose-volume relationship ensures the best clinical outcome in the high dose radiation therapy of thoracic tumors? A prospective approach.

Authors:  Christina Schröder; Rita Engenhart-Cabillic; Hilke Vorwerk; Michael Schmidt; Winfried Huhnt; Eyck Blank; Dietrich Sidow; André Buchali
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

6.  Simultaneously modulated accelerated radiation therapy reduces severe oesophageal toxicity in concomitant chemoradiotherapy of locally advanced non-small-cell lung cancer.

Authors:  Enrique Chajon; Julien Bellec; Joël Castelli; Romain Corre; Mallorie Kerjouan; Elisabeth Le Prisé; Renaud De Crevoisier
Journal:  Br J Radiol       Date:  2015-09-28       Impact factor: 3.039

7.  Hypofractionated radiation therapy in the management of locally advanced NSCLC: a narrative review of the literature on behalf of the Italian Association of Radiation Oncology (AIRO)-Lung Working Group.

Authors:  Giuseppe Parisi; Rosario Mazzola; Patrizia Ciammella; Giorgia Timon; Alessandra Fozza; Davide Franceschini; Federico Navarria; Alessio Bruni; Marco Perna; Niccolò Giaj-Levra; Filippo Alongi; Vieri Scotti; Marco Trovo
Journal:  Radiol Med       Date:  2018-10-27       Impact factor: 3.469

8.  Radiobiological evaluation of simultaneously dose-escalated versus non-escalated intensity-modulated radiation therapy for patients with upper thoracic esophageal cancer.

Authors:  Bao-Tian Huang; Li-Li Wu; Long-Jia Guo; Liang-Yu Xu; Rui-Hong Huang; Pei-Xian Lin; Jian-Zhou Chen; De-Rui Li; Chuang-Zhen Chen
Journal:  Onco Targets Ther       Date:  2017-04-19       Impact factor: 4.147

9.  Different definitions of esophagus influence esophageal toxicity prediction for esophageal cancer patients administered simultaneous integrated boost versus standard-dose radiation therapy.

Authors:  Bao-Tian Huang; Rui-Hong Huang; Wu-Zhe Zhang; Wen Lin; Long-Jia Guo; Liang-Yu Xu; Pei-Xian Lin; Jian-Zhou Chen; De-Rui Li; Chuang-Zhen Chen
Journal:  Sci Rep       Date:  2017-03-09       Impact factor: 4.379

10.  IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung Cancer.

Authors:  David B Landau; Laura Hughes; Angela Baker; Andrew T Bates; Michael C Bayne; Nicholas Counsell; Angel Garcia-Alonso; Susan V Harden; Jonathan D Hicks; Simon R Hughes; Marianne C Illsley; Iftekhar Khan; Virginia Laurence; Zafar Malik; Helen Mayles; William Philip M Mayles; Elizabeth Miles; Nazia Mohammed; Yenting Ngai; Emma Parsons; James Spicer; Paula Wells; Dean Wilkinson; John D Fenwick
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-03-28       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.